Sanofi-Aventis Receives Complete Response Letter from the FDA for Eplivanserin (Ciltyri) Submission

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company's New Drug Application (NDA) for eplivanserin (Ciltyri ).

The details can be read here.